In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Amgen recently faced a legal setback, with a U.S. District Court jury finding the company liable for antitrust violations and awarding Regeneron Pharmaceuticals $406.8 million in damages.

THOUSAND OAKS, Calif., May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday, May 21, 2025.

(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

Investing.com -- S&P Global Ratings has revised the rating outlook for Amgen Inc (NASDAQ:AMGN). from negative to stable following the company’s consistent reduction of its debt. The ...

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...

This group includes Amgen (NASDAQ: AMGN) and Viking Therapeutics (NASDAQ: VKTX), two drugmakers that have produced phase 2 clinical trial data for their leading weight management candidates.

A Delaware federal trial jury found Thousand Oaks, California-based drug company Amgen Inc. liable Thursday for federal and state antitrust violations amounting to more than $400 million in damages.

Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws ...

Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse portfolios. Amgen boasts one of the largest portfolios in the biotech industry ...